Biogen Inc. (20)
Browse by Contract Category
Contracts
-
Registration Rights Agreement, dated February 16, 2021, between Biogen Inc. and Deutsche Bank Securities Inc. and Citigroup Global Markets, Inc. with respect to the 3.250% Senior...
(Filed With SEC on February 16, 2021)
-
Letter regarding employment arrangement of Chirfi Guindo dated October 12, 2017
(Filed With SEC on February 3, 2021)
-
Description of Securities
(Filed With SEC on February 6, 2020)
-
Form of 3.250% Senior Notes due 2051, in the form of a Global Note bearing a Regulation S legend
(Filed With SEC on February 16, 2021)
-
Form of 3.250% Senior Notes due 2051, in the form of a Global Note bearing a private placement legend
(Filed With SEC on February 16, 2021)
-
Third Supplemental Indenture, dated February 16, 2021, between Biogen Inc. and U.S. Bank National Association
(Filed With SEC on February 16, 2021)
-
Second Supplemental Indenture, dated April 30, 2020, between Biogen Inc. and U.S. Bank National Association, including the forms of Global Notes attached as Exhibit A and Exhibit...
(Filed With SEC on February 3, 2021)
-
Biogen Inc. Executive Severance Policy - U.S. Executive Vice President, as amended effective July 13, 2020
(Filed With SEC on October 21, 2020)
-
Separation Agreement between Biogen Inc. and Jeffrey Capello dated July 16, 2020
(Filed With SEC on October 21, 2020)
-
Letter regarding employment arrangement of Michael McDonnell dated July 16, 2020
(Filed With SEC on October 21, 2020)
-
Second Supplemental Indenture, dated April 30, 2020, between the Company and U.S. Bank National Association, including the forms of Global Notes attached as Exhibit A and Exhibit...
(Filed With SEC on April 30, 2020)
-
Underwriting Agreement, dated April 27, 2020, by and among the Company, Goldman Sachs & Co. LLC, BofA Securities, Inc. and J.P. Morgan Securities LLC, as representatives of the...
(Filed With SEC on April 30, 2020)
-
Credit Agreement, dated as of January 28, 2020, among Biogen Inc., Bank of America, N.A., as administrative agent, swing line lender and the L/C issuer, and the other lenders...
(Filed With SEC on February 3, 2020)
-
Annual Retainer Summary for Board of Directors (effective as of January 1, 2020)
(Filed With SEC on October 22, 2019)
-
Biogen Inc. Executive Severance Policy - U.S. Executive Vice President, as amended effective June 19, 2019
(Filed With SEC on July 24, 2019)
-
Form of performance stock units award agreement (cash settled) under the Biogen Inc. 2017 Omnibus Equity Plan (for grants commencing in July 2019)
(Filed With SEC on July 24, 2019)
-
Form of performance stock units award agreement under the Biogen Inc. 2017 Omnibus Equity Plan (for grants commencing in July 2019)
(Filed With SEC on July 24, 2019)
-
Form of market stock unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan (for grants commencing in July 2019)
(Filed With SEC on July 24, 2019)
-
Biogen Inc. 2019 Form of Performance-Based Management Incentive Plan. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019
(Filed With SEC on April 24, 2019)
-
Annual Retainer Summary for Board of Directors
(Filed With SEC on February 6, 2019)